Literature DB >> 8689637

Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.

A A Jagasia1, J A Block, A Qureshi, M O Diaz, T Nobori, S Gitelis, A P Iyer.   

Abstract

Deletions on the short arm of chromosome 9 (9p21 region) have been reported in a number of hematopoietic and solid tumors. These aberrations on 9p have been previously associated with the loss of the interferon gene cluster and the gene for methylthioadenosine phosphorylase (MTAP), localized to the 9p21-22 region. Recently, two putative tumor suppressor gene(s) CDKN2 and MTS2 have been mapped to the 9p21 region, and shown to be deleted in a large number of tumors including leukemias, melanomas, bladder cancers and brain tumors. We have previously reported a similar 9p21 abnormality and deletions of the CDKN2 and MTS2 genes in a myxoid chondrosarcoma cell line and its subclones. In this study we report consistent abnormalities of chromosome 9 in additional chondrosarcomas examined by a detailed cytogenetic and molecular analysis. Seven chondrosarcoma cell lines, one primary chondrosarcoma, and a benign chondroma were examined. Four of the seven tumor cell lines examined showed grossly visible aberrations of chromosome 9. Molecular analysis of these chondrosarcoma cell lines revealed hemizygous deletions of the interferon genes, and the absence of the MTAP gene, protein or activity. In addition, four of the seven chondrosarcoma cell lines also showed deletions of the CDKN2 and/or MTS2 putative tumor suppressor genes, or the absence of the CDKN2 protein product. No such chromosome 9 related aberrations were detected in the benign chondroma. These data suggest that chromosome 9p21 abnormality, and deletions of the CDKN2 and MTS2 tumor suppressor genes may be a significant event in the development of chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8689637     DOI: 10.1016/0304-3835(96)04274-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  A thin-layer model for viscoelastic, stress-relaxation testing of cells using atomic force microscopy: do cell properties reflect metastatic potential?

Authors:  Eric M Darling; Stefan Zauscher; Joel A Block; Farshid Guilak
Journal:  Biophys J       Date:  2006-12-08       Impact factor: 4.033

2.  EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas.

Authors:  J V Bovée; A M Cleton-Jansen; W Wuyts; G Caethoven; A H Taminiau; E Bakker; W Van Hul; C J Cornelisse; P C Hogendoorn
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

3.  Regulation of human methylthioadenosine phosphorylase gene by the CBF (CCAAT binding factor)/NF-Y (nuclear factor-Y).

Authors:  Yuwaraj Kadariya; Kaname Nakatani; Junji Nishioka; Takahiko Fujikawa; Warren D Kruger; Tsutomu Nobori
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

4.  Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development.

Authors:  D Gottschalk; M Fehn; S Patt; W Saeger; T Kirchner; T Aigner
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

5.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

6.  New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis.

Authors:  Jonathan Cm Clark; Toru Akiyama; Crispin R Dass; Peter Fm Choong
Journal:  Cancer Cell Int       Date:  2010-06-28       Impact factor: 5.722

7.  Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63.

Authors:  Narasimharao V Marella; Michael J Zeitz; Kishore S Malyavantham; Artem Pliss; Sei-ichi Matsui; Sandra Goetze; Juergen Bode; Ivan Raska; Ronald Berezney
Journal:  Chromosome Res       Date:  2008-11-15       Impact factor: 5.239

8.  Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.

Authors:  Danielle Meijer; Hans Gelderblom; Marcel Karperien; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn; Judith V M G Bovee
Journal:  Clin Sarcoma Res       Date:  2011-07-25

9.  No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Authors:  Elisabeth F P Peterse; Arjen H G Cleven; Yvonne De Jong; Inge Briaire-de Bruijn; Jonathan A Fletcher; Erik H J Danen; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.